Search Results

240 results for NOVL

The Genesis Mission Has a 270-Day Timeline – And You’re Already Late

By Luke Lango, InvestorPlace Senior Investment Analyst

The government is taking equity stakes in American companies. Here are the next Genesis Mission stocks to buy before the capital hits.

How AI Could Lead to the “Death of the Spirit”

By Jeff Remsburg, Editor, Investing Insider

In the days ahead, we’ll revisit several Digests from 2025 (and one from last year) that helped frame important questions, spotlighted emerging risks and opportunities,…

The Data Point that Saved Christmas

By Jeff Remsburg, Editor, Investing Insider

5 Option Trades on Hot Takeover Rumors

By Jon Ogg

It seems we hear rumors every day about which company is next in line to be acquired. Find out how to play the hottest ones.

14 Stocks to Buy Near New 52-Week Highs

By Jim Woods, Editor-in-Chief, Successful Investing, Intelligence Report, Bullseye Stock Trader

Some simple trading strategies involve buying oversold stocks with great numbers — but another great investment strategy for your retirement money is to buy stocks…

Novell — Stealthy Market Leader

By Nick Atkeson and Andrew Houghton

NOVL is a high-quality, cash-flow-positive software company that has been almost forgotten in this two-month market rally.

Stock Up on Kroger Call Options

By Chris Johnson and Jon Lewis, Contributors

A bullish options trade ahead of Kroger Co. (NYSE: KR) earnings could pay off.

TIVO Options – Speculative TIVO Options Could Record Big Profits

By Jon Ogg

TiVo Inc. (NASDAQ: TIVO) was cut in half following news that its patent victory would be heard in appeals court. But a reversal trade could…

Watching the End of the Week

By Sam Collins, InvestorPlace Chief Technical Analyst

A strong end-of-week rally in the face of more bad news could get the bulls in a holiday-party mood.

10.4% Youth Unemployment – Is Your Job Next?

By Jeff Remsburg, Editor, Investing Insider

Sweet 16 Option Trades

By OptionsZone Experts

Top traders offer up their game-winning ideas for OptionsZone’s Annual March Madness Contest.

Kindle Delivers for Amazon

By Anthony John Agnello, Consumer and Technology Writer

The electronic reader keeps its grip on the digital book market, becoming the company’s all-time bestseller.

Why Luke Lango Hasn’t Called the Bottom

By Jeff Remsburg, Editor, Investing Insider

8 Companies Poised to Soar From Nvidia and OpenAI’s $100 Billion Alliance

By Luke Lango, InvestorPlace Senior Investment Analyst

Nvidia and OpenAI just launched a $100 billion alliance. Discover the eight companies set to profit from this historic AI deal.

Harry Potter and the Cursed Child: 9 Things to Know

By Karl Utermohlen, InvestorPlace Writer

‘Harry Potter and the Cursed Child’ is the name of the new JK Rowling book and it will be released on July 31. Here are…

3 Best Stocks to Buy for Soaring Oil Prices

By John Divine, InvestorPlace Assistant Editor

If you’re looking for stocks to buy and believe in rising oil prices, it doesn’t get much better than these three names.

How to Decide If Fastly Is a $70 or $90 Stock

By Will Ashworth, InvestorPlace Contributor

Despite the TikTok threat seemingly over for Fastly, FSLY stock doesn’t seem like it wants to take the next leg up on its way to…

Can Barnes & Noble’s Nook Grow Its Market Share?

By Cynthia Wilson, Consumer Finance & Funds Writer

The e-reader wars rage on, as Barnes & Noble’s Nook battles hard for market share.

3 Underappreciated Biotech Stocks to Buy Now: May 2024

By Terel Miles, InvestorPlace Contributor

Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR), and Novo Nordisk (NVO) are the top 3 biotech stocks to buy in May 2024.

3 Biotech Stocks Set to Double by 2028

By Terel Miles, InvestorPlace Contributor

These are three of the top biotech stocks set to double by 2028. Add them to your portfolio to maximize your potential gains.

Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making

By Terel Miles, InvestorPlace Contributor

These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward.

Will ‘Casual Vacany’ Bump ‘Fifty Shades of Grey’?

By Nate Wooley, InvestorPlace Writer

The ‘Harry Potter’ author is moving into adult themes in her new book. With 1 million pre-orders already, she already has another hit.

Sorrento Therapeutics Remains a Buy Between $6 and $6.50

By Will Ashworth, InvestorPlace Contributor

Sorrento Therapeutics has seen SRNE stock close between $5.76 and $8.20 in the past month. Here’s why it’s time for investors to be careful. 

As the Purchase Orders Build, Workhorse Group Will Ultimately Succeed

By Will Ashworth, InvestorPlace Contributor

Workhorse Group got another purchase order for its C-1000. Eventually, this will translate into real growth for WKHS stock. 

1 – 10 of 240 results